Latest News
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
3 February 2026 - US-based clinical-stage precision medicine company Relay Therapeutics, Inc. (NASDAQ: RLAY) on Tuesday said the US Food and Drug Administration has granted Breakthrough Therapy designation to zovegalisib in combination with fulvestra...
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
3 February 2026 - Japanese healthcare company Daiichi Sankyo Co Ltd (TYO:4568) and British-Swedish biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (Nasdaq:AZN) announced on Tuesday that the US Food and Drug Administration (FDA) has acce...
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
3 February 2026 - Vaccine company Valneva SE (Nasdaq:VALN) (Euronext Paris:VLA) and biomedical research centre Instituto Butantan said on Tuesday that they have initiated a Pilot Vaccination Strategy in Brazil using Valneva's single-shot chikung...
Lupin launches Dasatinib tablets in US market
3 February 2026 - Lupin Limited (BSE:500257) (NSE:LUPIN), an India-based global pharmaceutical company, announced on Monday that it has launched its Dasatinib Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, in the United States.This follows ...
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
3 February 2026 - WuXi Biologics (HKG:2269), a China-based global Contract Research, Development, and Manufacturing Organisation (CRDMO), announced on Monday that it has entered into a licence and research service agreement with US biopharmaceutical ...